PMID- 9630360
OWN - NLM
STAT- MEDLINE
DCOM- 19980804
LR  - 20161019
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 124
IP  - 1
DP  - 1998 May
TI  - Effect of chronic bradykinin B2 receptor blockade on blood pressure of conscious 
      Dahl salt-resistant rats.
PG  - 197-205
AB  - 1. In this study 3 protocols were utilized to determine the role of endogenous 
      kinins in the resistance of the inbred Dahl (Rapp) salt-resistant (SR/Jr) rats to 
      high salt diet-induced blood pressure elevation. 2. The bradykinin B2 receptor 
      antagonist, Hoe 140 (D-Arg[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin) at doses of 
      either 10-20 or 20-40 nmol day(-1) (subcutaneously (s.c), via osmotic minipumps, 
      for either 1 or 3 weeks during a high (8%) salt diet) effectively blocked or 
      attenuated the hypotensive responses to 100-1000 ng of bradykinin. 3. In the 
      first protocol, 5 week old SR/Jr rats treated with Hoe 140 (10-20 nmol day(-1), n 
      = 9, s.c., via osmotic minipumps) for 3 weeks and concomitantly fed high (8%) 
      NaCl diet had significantly higher conscious tail cuff blood pressures (BPc) at 1 
      and 3 weeks when compared with rats treated with vehicle (0.9% NaCl, n = 6). The 
      differences in BPc between the 2 groups were 13 mmHg (P < 0.001) after 1 week and 
      8 mmHg (P < 0.05) after 3 weeks of treatment. 4. In the second protocol, 5 week 
      old SR/Jr rats were treated with Hoe 140 (20-40 nmol day(-1), n = 8, s.c., via 
      osmotic minipumps) or vehicle (n = 8) for 3 weeks. During the first week of 
      treatment the rats were fed normal (0.8%) NaCl diet. The rats were then switched 
      to 8% NaCl for 2 remaining weeks of the protocol. The mean BPc of Hoe 140-treated 
      rats was not significantly different from that of the vehicle-treated rats when 
      fed 0.8% NaCl diet. In contrast, rats treated with Hoe 140 and concomitantly fed 
      high (8%) NaCl diet had significantly increased BPc (123+/-2 vs 111 +/- 1 mmHg, P 
      < 0.001 for the Hoe 140- and vehicle-treated rats, respectively). 5. In the third 
      protocol, treatment with Hoe 140 (20 40 nmol day(-1), s.c., via osmotic 
      minipumps) during high salt diet did not increase BPc in rats that were 
      pre-exposed to the high salt diet for 2 weeks. 6. At the end of 3 weeks of study, 
      blood pressure was measured via an arterial catheter during 
      pentobarbitone-induced anaesthesia. Rats treated with Hoe 140 for 1 or 3 weeks 
      had significantly lower mean arterial blood pressures than the vehicle-treated 
      rats. 7. Our findings suggest that in SR/Jr rats, kinin activation of bradykinin 
      B2 receptors at least partially contributes to early regulatory mechanisms that 
      resist an increase in blood pressure following exposure to a high salt diet. The 
      mechanism underlying the decreased blood pressure during pentobarbitone 
      anaesthesia of SR/Jr rats chronically treated with Hoe 140 has yet to be 
      elucidated.
FAU - Mukai, H
AU  - Mukai H
AD  - Department of Cell and Molecular Pharmacology and Experimental Therapeutics, 
      Medical University of South Carolina, Charleston, USA.
FAU - Fitzgibbon, W R
AU  - Fitzgibbon WR
FAU - Ploth, D W
AU  - Ploth DW
FAU - Margolius, H S
AU  - Margolius HS
LA  - eng
GR  - HL-17705/HL/NHLBI NIH HHS/United States
GR  - HL-44671/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Bradykinin Receptor Antagonists)
RN  - 0 (Receptor, Bradykinin B2)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 7PG89G35Q7 (icatibant)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Animals
MH  - Blood Pressure/*drug effects
MH  - Bradykinin/administration & dosage/*analogs & derivatives/pharmacology
MH  - *Bradykinin Receptor Antagonists
MH  - Heart Rate/drug effects
MH  - Kidney/drug effects/physiology
MH  - Rats
MH  - Receptor, Bradykinin B2
MH  - Sodium Chloride/administration & dosage
PMC - PMC1565358
EDAT- 1998/06/18 00:00
MHDA- 1998/06/18 00:01
PMCR- 1999/05/01
CRDT- 1998/06/18 00:00
PHST- 1998/06/18 00:00 [pubmed]
PHST- 1998/06/18 00:01 [medline]
PHST- 1998/06/18 00:00 [entrez]
PHST- 1999/05/01 00:00 [pmc-release]
AID - 0701797 [pii]
AID - 10.1038/sj.bjp.0701797 [doi]
PST - ppublish
SO  - Br J Pharmacol. 1998 May;124(1):197-205. doi: 10.1038/sj.bjp.0701797.